Intra-Cellular Therapies Inc (BSP:I2TC34)
R$ 83.36 0 (0%) Market Cap: 53.03 Bil Enterprise Value: 47.40 Bil PE Ratio: 0 PB Ratio: 8.38 GF Score: 41/100

Q2 2023 Intra-Cellular Therapies Inc Earnings Call Transcript

Aug 03, 2023 / 12:30PM GMT
Release Date Price: R$49.53
Operator

Good morning, and welcome to Intra-Cellular Therapies second quarter financial results conference call. (Operator Instructions) As a reminder, today's conference call is being recorded.

I would now like to turn the conference over to Dr. Juan Sanchez, Vice President, Corporate Communications and Investor Relations. Please go ahead.

Juan Fernando Sanchez
Intra-Cellular Therapies, Inc. - VP of Corporate Communications & IR

Good morning, and thank you all for being here. Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Mark Neumann, Chief Commercial Officer; Dr. Suresh Durgam, Chief Medical Officer; and Larry Hineline, Chief Financial Officer.

As a reminder, during today's call, we will be making certain forward-looking statements. These forward-looking statements are based on current information, assumptions and expectations. These are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot